ClinicalTrials.gg
Sign In
Drug

AB103 clinical trials

Also written AB103.

studies test it
4
open now
0
in phase 3
2
first study started
2010

How each study uses AB103 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

AB103 0.5 mg/kg
2

Development codes

AB103
2

Other names

reltecimod
1

Studies by the year they started

4 studies that test it; most in 2010 (1)

Studies that test AB103, by start year
YearStudies
20101
20111
20151
20181

By phase

A phase 1/2 study counts in both.

Phase 1
1
Phase 2
1
Phase 3
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Fasciitis, Necrotizing
1
Acute Kidney Injury
1

Who runs them

Industry 4 · Other 0

Atox Bio Ltd (4)

Studies

Open first, then newest update. How each study uses AB103 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 4

Codes

What other systems call AB103 · ClinicalTrials.gg INT000209

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.